COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus

Vista sencilla de ítem
dc.creatorScarfò, Lydia
dc.creatorChatzikonstantinou, Thomas
dc.creatorRigolin, Gian Matteo
dc.creatorQuaresmini, Giulia
dc.creatorMotta, Marina
dc.creatorVitale, Candida
dc.creatorGarcia-Marco, Jose Antonio
dc.creatorHernández-Rivas, José Ángel
dc.creatorMirás, Fatima
dc.creatorBaile, Mónica
dc.creatorMarquet, Juan
dc.creatorNiemann, Carsten U.
dc.creatorReda, Gianluigi
dc.creatorMunir, Talha
dc.creatorGimeno, Eva
dc.creatorMarchetti, Monia
dc.creatorQuaglia, Francesca Maria
dc.creatorVarettoni, Marzia
dc.creatorDelgado, Julio
dc.creatorIyengar, Sunil
dc.creatorJanssens, Ann
dc.creatorMarasca, Roberto
dc.creatorFerrari, Angela
dc.creatorCuéllar-García, Carolina
dc.creatorItchaki, Gilad
dc.creatorŠpaček, Martin
dc.creatorDe Paoli, Lorenzo
dc.creatorLaurenti, Luca
dc.creatorLevin, Mark-David
dc.creatorLista, Enrico
dc.creatorMauro, Francesca R.
dc.creatorŠimkovič, Martin
dc.creatorVan Der Spek, Ellen
dc.creatorVandenberghe, Elisabeth
dc.creatorTrentin, Livio
dc.creatorWasik-Szczepanek, Ewa
dc.creatorRuchlemer, Rosa
dc.creatorBron, Dominique
dc.creatorDe Paolis, Maria Rosaria
dc.creatorDel Poeta, Giovanni
dc.creatorFarina, Lucia
dc.creatorFoglietta, Myriam
dc.creatorGentile, Massimo
dc.creatorHerishanu, Yair
dc.creatorHerold, Tobias
dc.creatorJaksic, Ozren
dc.creatorKater, Arnon P.
dc.creatorKersting, Sabina
dc.creatorMalerba, Lara
dc.creatorOrsucci, Lorella
dc.creatorPopov, Viola Maria
dc.creatorSportoletti, Paolo
dc.creatorYassin, Mohamed
dc.creatorPocali, Barbara
dc.creatorBarna, Gabor
dc.creatorChiarenza, Annalisa
dc.creatorDos Santos, Gimena
dc.creatorNikitin, Eugene
dc.creatorAndres, Martin
dc.creatorDimou, Maria
dc.creatorDoubek, Michael
dc.creatorEnrico, Alicia
dc.creatorKalashnikova, Olga
dc.creatorHakobyan, Yervand
dc.creatorOrtiz Pareja, Macarena
dc.creatorPapaioannou, Maria
dc.creatorRossi, Davide
dc.creatorShah, Nimish
dc.creatorShrestha, Amit
dc.creatorStanca, Oana
dc.creatorStavroyianni, Niki
dc.creatorStrugov, Vladimir
dc.creatorTam, Constantine
dc.creatorZdrenghea, Mihnea
dc.creatorCoscia, Marta
dc.creatorStamatopoulos, Kostas
dc.creatorRossi, Giuseppe
dc.creatorRambaldi, Alessandro
dc.creatorMontserrat, Emili’
dc.creatorFoà, Robin
dc.creatorCuneo, Antonio
dc.creatorGhia, Paolo
dc.date.accessioned2020-07-16T19:27:32Z
dc.date.available2020-07-16T19:27:32Z
dc.date.created2020-07-09
dc.description.abstractenglishChronic lymphocytic leukemia (CLL) is a disease of the elderly, characterized by immunodeficiency. Hence, patients with CLL might be considered more susceptible to severe complications from COVID-19. We undertook this retrospective international multicenter study to characterize the course of COVID-19 in patients with CLL and identify potential predictors of outcome. Of 190 patients with CLL and confirmed COVID-19 diagnosed between 28/03/2020 and 22/05/2020, 151 (79%) presented with severe COVID-19 (need of oxygen and/or intensive care admission). Severe COVID-19 was associated with more advanced age (≥65 years) (odds ratio 3.72 [95% CI 1.79–7.71]). Only 60 patients (39.7%) with severe COVID-19 were receiving or had recent (≤12 months) treatment for CLL at the time of COVID-19 versus 30/39 (76.9%) patients with mild disease. Hospitalization rate for severe COVID-19 was lower (p < 0.05) for patients on ibrutinib versus those on other regimens or off treatment. Of 151 patients with severe disease, 55 (36.4%) succumbed versus only 1/38 (2.6%) with mild disease; age and comorbidities did not impact on mortality. In CLL, (1) COVID-19 severity increases with age; (2) antileukemic treatment (particularly BTK inhibitors) appears to exert a protective effect; (3) age and comorbidities did not impact on mortality, alluding to a relevant role of CLL and immunodeficiency.spa
dc.format.extent10 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.identifier.doihttps://doi.org/10.1038/s41375-020-0959-xspa
dc.identifier.issn1476-5551 (online)spa
dc.identifier.otherhttps://www.nature.com/articles/s41375-020-0959-xspa
dc.identifier.urihttps://hdl.handle.net/20.500.12010/10692
dc.publisherLeukemiaeng
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.sourcereponame:Expeditio Repositorio Institucional UJTLspa
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozanospa
dc.subjectchronic lymphocytic leukemiaspa
dc.subjectEuropean Research Initiative on CLLspa
dc.subject.lembSíndrome respiratorio agudo gravespa
dc.subject.lembCOVID-19spa
dc.subject.lembSARS-CoV-2spa
dc.subject.lembCoronavirusspa
dc.titleCOVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campusspa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.type.localArtículospa

Archivos

Bloque original

Mostrando 1 - 1 de 1
Miniatura
Nombre:
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus.pdf
Tamaño:
1.24 MB
Formato:
Adobe Portable Document Format
Descripción:
Documento Reservado
Descargar

Bloque de licencias

Mostrando 1 - 1 de 1
Miniatura
Nombre:
license.txt
Tamaño:
2.87 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Documentos científicos relacionados a la COVID-19

Carrera 4 # 22-61 Teléfono: (+57) 601 242 7030 - 018000111022 Fax: (+57) 601 561 2107 Bogotá D.C., Colombia

Fundación Universitaria de Bogotá Jorge Tadeo Lozano | Vigilada Mineducación

Institución de educación superior privada, de utilidad común, sin ánimo de lucro y su carácter académico es el de Universidad

Reconocimiento personería jurídica: Resolución 2613 del 14 de agosto de 1959 Minjusticia.

Institución de Educación Superior sujeta a inspección y vigilancia por el Ministerio de Educación Nacional.

Software DSpace copyright © 2002-2026 LYRASIS